Department of Clinical Laboratory, Xiamen Huli Guoyu Clinic, Co., Ltd., Xiamen, China.
Department of Clinical Laboratory, Xiamen Huli Guoyu Clinic, Co., Ltd., Xiamen, China.
Prog Mol Biol Transl Sci. 2019;161:181-210. doi: 10.1016/bs.pmbts.2018.09.002. Epub 2018 Oct 30.
As one of the largest families of cell membrane proteins, G protein-coupled receptors (GPCRs) are involved in regulating almost all physiological processes by transducing extracellular signals into the cytoplasm. Since the first discovery of naturally occurring mutations in Rhodopsin gene in 1990, hundreds of loss-of-function mutations in multiple GPCRs have been identified to be pathogenic for more than 30 diverse human diseases, making these defective receptors important drug targets for personalized medicine. In this review, we aim to elucidate the etiologies of five common inherited diseases caused by six of the most extensively studied GPCRs. The molecular basis and classification of inactivating mutations in GPCRs are also reviewed. The available therapeutic approaches directed against different classes of mutants, especially pharmacological chaperones targeting intracellularly retained mutants, reported during the past two decades, are systematically summarized.
作为细胞膜蛋白最大的家族之一,G 蛋白偶联受体(GPCRs)通过将细胞外信号转导到细胞质中,参与调节几乎所有的生理过程。自 1990 年首次发现视紫红质基因中的天然发生突变以来,已经鉴定出多种 GPCR 中的数百种失活功能突变是 30 多种不同人类疾病的致病因素,使这些有缺陷的受体成为个性化药物的重要药物靶点。在这篇综述中,我们旨在阐明由六个研究最广泛的 GPCR 引起的五种常见遗传性疾病的病因。还回顾了 GPCR 失活突变的分子基础和分类。系统总结了过去二十年报道的针对不同突变体类别的可用治疗方法,特别是针对细胞内保留突变体的药理学伴侣。